Health ❯ Obesity ❯ Treatment Options

Oral Medications

GLP-1 Drugs GLP-1 Agonists FDA Approval Elecoglipron Patient Adherence Patient Preferences Drug Efficacy Wegovy Pill GLP-1 Therapies Market Expansion Foundayo

AstraZeneca’s Oral GLP‑1 Elecoglipron Delivers Strong Phase 2 Weight and Blood‑Sugar Results

The company has launched a Phase 3 program to evaluate long‑term safety, refine dosing and run dedicated cardiovascular and kidney outcome trials.

Novo Nordisk Lifts 2026 Outlook as Wegovy Pill Powers Big Q1 Beat

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3